<Record><identifier xmlns="http://purl.org/dc/elements/1.1/">URN:NBN:SI:doc-E9H2YZSP</identifier><date>2025</date><creator>Stopinšek Rajšp, Mateja</creator><relation>documents/doc/E/URN_NBN_SI_doc-E9H2YZSP_001.pdf</relation><relation>documents/doc/E/URN_NBN_SI_doc-E9H2YZSP_001.txt</relation><format format_type="issue">4</format><format format_type="volume">76</format><format format_type="type">article</format><format format_type="extent">str. 288-293</format><identifier identifier_type="ISSN">0014-8229</identifier><identifier identifier_type="COBISSID_HOST">272032771</identifier><identifier identifier_type="URN">URN:NBN:SI:doc-E9H2YZSP</identifier><language>slv</language><publisher publisher_location="Ljubljana">Slovensko farmacevtsko društvo</publisher><source>Farmacevtski vestnik</source><rights>BY-NC</rights><subject language_type_id="eng">anaplastic lymphoma kinase inhibitors</subject><subject language_type_id="slv">anaplastična limfomska kinaza</subject><subject language_type_id="eng">clinical case</subject><subject language_type_id="slv">klinični primer</subject><subject language_type_id="slv">Neželeni učinki</subject><subject language_type_id="slv">Pljučni rak</subject><subject language_type_id="slv">Tarčna zdravila</subject><title>Neželeni učinki zdravljenja pljučnega raka s tarčnimi zdravili proti anaplastični limfomski kinazi</title><title>Adverse drug reactions of targeted therapy with anaplastic lymphoma kinase inhibitors in patients with lung cancer</title></Record>